- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
Vol. 8, No. 4
Winter 2019
Relevant court decisions highlighted in this issue:
- Novartis Pharms. Corp v. Breckenridge Pharm. Inc.
A post-URAA patent that issues after, and expires before, a pre-URAA patent does not qualify as a double-patenting reference against the pre-URAA patent. - Novartis AG v. Ezra Ventures LLC
“Effectively” extending the term of a second patent was not a violation of 35 U.S.C. § 156. - Tris Pharma Inc. v. Actavis Labs. Fl, Inc.
On appeal, the Federal Circuit found that the district court’s conclusions of law related to its obviousness findings were based on inadequate factual findings, and therefore vacated and remanded.
Relevant ANDA updates highlighted in this issue:
- ANDA Approvals
- ANDA Litigation Settlements
- Generic Launches
- New ANDA Cases
Related Professionals
Christopher A. Pinahs
Partner
Patent-in-suit is invalid because certain limitations are inherent in the prior art.
The court disagreed with Plaintiff’s argument that the labeling, promotional materials, and samples related to Defendants’ product showed intent to induce infringement, and granted summary judgment in Defendants’ favor.
“Effectively” extending the term of a second patent was not a violation of 35 U.S.C. § 156.
A post-URAA patent that issues after, and expires before, a pre-URAA patent does not qualify as a double-patenting reference against the pre-URAA patent.
Judgment on the pleadings was appropriate where plaintiff’s Answer to counterclaims conceded non-infringement at the time of the counterclaim.
District court’s finding that plaintiff demonstrated a likelihood of success on the merits was reversed on the basis of (i) specification disclaimer and (ii) issue preclusion.
On appeal, the Federal Circuit found that the district court’s conclusions of law related to its obviousness findings were based on inadequate factual findings, and therefore vacated and remanded.
The word “target,” appearing twice in each of the independent asserted claims is indefinite, thereby rendering the patents-in-suit invalid on summary judgment.
Plaintiff’s testing of representative ANDA products demonstrated literal infringement.
The claims of the patent-in-suit were infringed, and though adequately described, they were found invalid as obvious.
After limited discovery on plaintiffs’ alter-ego theory, the court granted defendant’s motion to dismiss for lack of personal jurisdiction.
The Federal Circuit concluded that the district court did not err in invalidating all asserted claims of the Copaxone patents as obvious.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.